Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Can you guess the (lightly disputed) champion of healthcare AI suppliers? Here’s a hint. This company caters to physicians and just this week reached a valuation of $12B.
UnitedHealth Group CEO Stephen Hemsley is expected to make the announcement in front of Congress, where he will also offer other policy solutions. The company said it’s still working out details on how to best distribute its profits to customers.
Extravascular ICDs were developed to avoid complications such as vascular injuries, lead fractures and lead infections. Although rare, these issues can cause serious, life-threatening complications for patients.
The insurer is planning to reduce reimbursement timelines for hospitals in Oklahoma, Idaho, Minnesota and Missouri from 30 days to 15. The details are unclear, but the company said the framework could extend nationwide.
Gen Xers and their elders tend to believe AI will do more harm than good. More than half of American adults 50 and older place themselves in that somewhat cynical category.
Over 97% of all counties in the U.S. see high or very high levels of consolidation in Medicare Advantage markets, with UnitedHealthcare and Humana owning the most plans nationwide.
Former Steward Health Care CEO Ralph de la Torre, MD, and other executives are accused in a $1.4 billion legal filing of paying themselves hundreds of millions of dollars in bonuses, despite the health system being insolvent.
In a new report, the New York Times details multiple incidents of the insurance giant using legal threats to silence social media users and news outlets, citing the murder of Brian Thompson and the threat of rising violence as the basis for its claims.
Shareholders of the retail pharmacy giant voted in favor of the terms of the sale to Sycamore Partners for $11.45 a share. The deal is expected to close later this year.